We measured basal plasma prolactin concentrations (in samples obtained during the early follicular phase) in 25 normal (control) women and in a similar group of 40 patients with a long-standing history of infertility. The infertile patients were all ovulating regularly, and had been unsuccessfully treated with clomiphene and in some cases dydrogesterone and human menopausal gonadotrophin. Although none of the patients had plasma prolactin concentrations > 1000 uU/ml, 47 5% of the estimations were greater than 1 standard deviation (SD) above the mean established for our control group. This difference was highly significant (P <0001). Treatment with various bromocriptine regimens effectively reduced prolactin concentrations to below normal in all cases, and 16 pregnancies followed-13 during bromocriptine treatment and three in the first post-treatment cycle. The cumulative conception rate was 634% after 10 months' treatment. Introduction Plasma prolactin concentrations are consistently raised in patients with Chiari-Frommel syndrome' and in some amenorrhoeic women with or without galactorrhoea.2-6 Treatment with bromocriptine (2-bromo-a-ergocryptine) has effectively reduced circulating prolactin concentrations, and
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Introduction
Plasma prolactin concentrations are consistently raised in patients with Chiari-Frommel syndrome' and in some amenorrhoeic women with or without galactorrhoea.2-6 Treatment with bromocriptine (2-bromo-a-ergocryptine) has effectively reduced circulating prolactin concentrations, and induced ovulation (and conception) in most.'-8 Bromocriptine may also restore cyclical menstruation in euprolactinaemic amenorrhoea,9 and improve luteal function in normally men- struating patients who nevertheless have hyperprolactinaemia and short luteal phases.10 11 We undertook the present study to determine whether an appreciable number of regularly ovulating women with long-standing infertility also have raised plasma prolactin concentrations, and to determine the therapeutic effectiveness of treatment with bromocriptine for this particular type of infertility.
Patients and methods
Initially 40 patients with long-standing infertility (range 2-10 years) were selected for assessment of basal prolactin concentrations and treatment with bromocriptine. Although 13 (325 5%) of the women had had a previous pregnancy this had ended in an abortion in 10 (25 %o) and a full-term intrauterine death in one patient. Only two patients had given birth to a living child. These women had all been fully investigated and were found to be ovulating regularly, with cycles of normal length (25-35 days) . No reason for their infertility was shown by routine investigations (which included seminal analysis, hysterosalpingogram in all patients, and laparoscopy in 20), but we felt that these patients were similar to women with defective luteal phases."2 13 Preliminary findings showed that none of these women had a short luteal phase-that is, a luteal phase lasting less than 10 days (criteria of Sherman and Korenman'4)-and that they had ovulated in the cycles investigated. We considered ovulation to have occurred if a surge of luteinising hormone preceded a rise of plasma progesterone in all cases. Blood samples for prolactin measurement were obtained on two occasions (between 0800 and 1000 hours) within the first five days of each patient's basal cycle. Similar samples were obtained at the same time in the cycle from a group of 25 normal (control) women-that is, fertile women with no known gynaecological or medical abnormality or relevant drug history. Plasma was separated within 45 minutes and stored at -20°C until assayed for prolactin.
Hormone assay-Plasma prolactin was measured by radioimmunoassay,'5 using the reagents provided by the National Pituitary Agency (antiserum and hormone for labelling), and the standard distributed by the Medical Research Council Division of Biological Standards (Research Standard A71/222), which was used to calibrate our own laboratory standard (a pool of serum from lactating women). All results are expressed in ,uU/ml in terms of the MRC 71/222 preparation. (Approximately 40 pU/ml of this are equivalent to 1 ng/ml NIH VLS1). All the prolactin estimations were performed in two assays to eliminate possible interassay variation. Treatment regimen-The patients were randomly allocated to one of four groups. Bromocriptine (Parlodel, Sandoz) was given throughout the cycle in one of the following dose regimens: 2 5 mg twice daily; 1-25 mg thrice daily; 1 25 mg twice daily; and 1 25 mg twice daily with 50 mg clomiphene citrate (Clomid, Merrell) on days 2 to 6 of the cycle. A few patients were eventually included in more than one treatment group. The effect of treatment on the plasma prolactin concentrations was monitored for the first two treatment cycles by assaying a single plasma sample obtained as above within the first five days of each cycle. Blood was not collected for prolactin estimation until 48 hours after the start of treatment, to allow the prolactin concentrations to stabilise.
Results
The distribution of basal prolactin concentrations in the normal women and the infertile patients are shown in fig 1. Although the ranges of plasma prolactin were not greatly different, the distribution for the infertile women was clearly shifted to the right. Furthermore, neither of these distributions was "normal," and probit analysis showed them to conform much more closely to log-normal distributions. For this reason we used log-means ( ±SD) to define our normal range and for statistical comparisons with the infertile group (table I). The difference between the mean concentrations was highly significant (P < 0 001, Student's t test). Similarly, when the number of prolactin estimations greater than 1 SD above the normal mean ( 300 :sU ml) were compared for the two groups, the differences (18400 of the normal values and 47 5 0 of the infertile patients' results) were again significant (P < 0-001, 24 test).
Treatment with bromocriptine reduced prolactin concentrations to below the normal range in most cases (normal mean -2 SD is 106 itU/ml), and sometimes to below the lower limit of sensitivity of the assay (50 tU/rml). The results of treatment with the different regimens are shown in table II, and again log-mean values have been used. Sixteen of the infertile patients conceived, five within the first two treatment cycles, eight during subsequent treatment cycles, and three during the first cycle after withdrawal of treatment. Unfortunately, two of the pregnancies in the bromocriptine plus clomiphene group were ectopic (tubal). Nine of the remaining pregnancies resulted in the term delivery of a normal infant and four were continuing. The cumulative conception rate" at the end of 10 treatment cycles was 63 4°0 (table III) . If the three pregnancies which occurred in the first post-treatment cycle were omitted, the cumulative conception rate after 10 cycles became 55 1 'o. Mean basal prolactin concentration was 275 .cU ml in the patients who conceived and 311 :sU ml in the patients who did not become pregnant. This difference was not significant.
Discussion
We initially decided to measure the prolactin concentration in only two samples from the first five days of the cycle so that we could measure all the samples in two assays. The day-to-day variation in plasma prolactin concentrations seems to be least at this stage of the cycle. I Our normal mean and range of prolactin concentrations is slightly lower than those quoted by other authors,2 18 probably because we only included samples obtained in the early follicular phase, and plasma prolactin levels tend to rise'I as the cycle progresses.
None of the infertile women had prolactin concentrations greater than 1000 uU/ml, and therefore could not be considered to have gross hyperprolactinaemia. Nevertheless, the distribution of prolactin concentrations was significantly higher than in our normal group, although treatment with bromocriptine effectively suppressed circulating prolactin concentrations to below normal at all the dose levels studied. Life-tables'6 were used to calculate the cumulative conception rate because this method includes patients who cease treatment before the end of a study, and thus permits valid comparisons to be made between different studies. The cumulative conception rate reported here after bromocriptine treatment is dramatically different from the spontaneous conception rate obtained in a similar group of patients who were given no treatment.2 In the latter series only 43", of the patients conceived spontaneously in a period of eight years (10°, in the first year of follow-up, whereas 63°,, of the patients in this study conceived in 10 months). The conception rate after bromocriptine in these infertile women is still less than the reported rates for a normal population. " 22 At this stage it is premature to speculate about the direct or indirect effects of bromocriptine on follicular maturation and function of the corpus luteum. The role of prolactin in the regulation of reproduction in these women is undoubtedly complex,22 and may well be only loosely related to circulating prolactin concentrations.' Some mechanism apart from a mere reduction in plasma concentrations is needed to explain the resumption of menses in some euprolactinaemic women9 and not others.2 In our own series of ovulating women, the pregnancies that occurred were not among the patients with the highest prolactin concentrations, but were evenly distributed throughout the range of prolactin concentrations measured. Nonetheless, it seems most unlikely that the number of pregnancies obtained here in a group of women who normally are very difficult to treat successfully could be fortuitous and unrelated to bromocriptine administration. This new and apparently successful use of bromocriptine2; needs much careful research to establish not only the precise mode of action but also the type of ovulatory but infertile woman who is most likely to benefit from it.
